...from the rare hematologic and systemic complement-mediated disorders company in August. Musil was CBO at Personalis Inc....

...served as the cancer company’s VP of investor relations and corporation communications. Cancer genomics company Personalis Inc....
...which he founded. Robin Sawka, BioCentury Staff Editas Medicine Inc. Immunocore Ltd. Spruce Biosciences Inc. Frazier Healthcare Partners Horama S.A. Nordic Nanovector ASA Personalis Inc. Centogene Acesion...

...Inc. (NASDAQ:AKRO) 6/19/19 $105.8 $446.5 $534.4 20% Atreca Inc. (NASDAQ:BCEL) 6/19/19 $125.0 $455.3 $504.6 11% Personalis Inc....
...greenshoe three days after the IPO priced. An even greater exception than Prevail might be Personalis Inc....
...HKEX:03692), Lianyungang, China Mirum Pharmaceuticals Inc., San Francisco, Calif. Morphic Holding Inc. (NASDAQ:MORF), Waltham, Mass. Personalis Inc....

...that priced at $18, above its proposed $14-$16 range. The next day, cancer genomics company Personalis Inc....
...is led by Edward Kaye, who was previously CEO of DMD company Sarepta Therapeutics Inc. Personalis’...
...Foster City, Calif. Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Personalis Inc....

...offerings that were within expectations. Demand was highest for the listing by cancer genomics company Personalis Inc....
...above its proposed range, then climbed $13.25 (78%) to $30.25 across two days of trading. Personalis...
...6.7 million shares at $14-$16. Underwriters are Morgan Stanley, BofA Merrill Lynch, Cowen and Oppenheimer. Personalis’...

...Stoke and Personalis set similar ranges for their NASDAQ IPOs Friday, which could raise a combined...
...of $200 million. Genetic diseases company Stoke Therapeutics Inc. (Bedford, Mass.) and cancer genomics company Personalis Inc....
...would be valued at $454 million; Personalis' valuation would be $427.5 million. Elizabeth S. Eaton, Staff Writer Personalis Inc. Stoke...

...to join the IPO queue, Personalis Inc. (Menlo Park, Calif.) and Stoke Therapeutics Inc. (Bedford, Mass.). Personalis...
...immune microenvironment from a single tissue sample. Lightspeed Venture Partners holds the biggest stake in Personalis...
...Fibroblast growth factor 21 Elizabeth S. Eaton, Staff Writer AKR-001 GSK2894512, WBI-1001, tapinarof Akero Therapeutics Inc. Amgen Inc. Atreca Inc. BridgeBio Pharma LLC Personalis Inc. Prevail...

...the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN), Neon Therapeutics Inc. (Cambridge, Mass.) and Personalis Inc....
...for Cancer Research Ltd. MedImmune LLC Memorial Sloan Kettering Cancer Center National Cancer Centre Singapore Neon Therapeutics Inc. Netherlands Cancer Institute Personalis Inc. Roche Roswell...

...LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.), Neon Therapeutics Inc. (Cambridge, Mass.) and Personalis Inc....
...Leon Advaxis Inc. Agenus Inc. Amgen Inc. AstraZeneca plc BioNTech AG Bristol-Myers Squibb Co. Cancer Research Institute Genentech Inc. ISA Pharmaceuticals B.V. MedImmune LLC Neon Therapeutics Inc. Personalis Inc. Roche The...

...made five other biotech investments, including cancer diagnostics play Guardant Health Inc. and genomics company Personalis Inc....
...for a series A round; and the experienced management team. MacQuitty is also chairman of Personalis...